NKTR Nektar Therapeutics

  1. Stocks
  2. Healthcare
  3. NASDAQ: NKTR

Price (delayed)

$70.59

Market cap

$2.38B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.23

Enterprise value

$2.32B

?
Relative Growth: Rel. Growth: 15
Relative Strength: Rel. Strength: 90
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 30

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), ...

Highlights
Nektar Therapeutics's quick ratio has soared by 115% from the previous quarter
Nektar Therapeutics's gross margin has increased by 34% YoY
The net income has declined by 19% year-on-year but it has grown by 3.6% since the previous quarter
The revenue has contracted by 36% YoY
The gross profit has declined by 15% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.nektar.com
Peers: PFE MRK AMGN BAX

Key stats

What are the main financial stats of NKTR

NKTR stock price

How has the Nektar Therapeutics stock price performed over time
Intraday
-0.11%
1 week
-1.07%
1 month
-0.63%
1 year
207.45%
YTD
66.96%
QTD
1.12%

Financial performance

How have Nektar Therapeutics's revenue and profit performed over time
Revenue
$55.63M
Gross profit
$55.63M
Operating income
-$134.62M
Net income
-$158.1M
Gross margin
100%
Net margin
-284.2%
The net margin has shrunk by 86% YoY but it has increased by 4.3% QoQ
The operating margin has plunged by 85% YoY but it has grown by 4.6% from the previous quarter
The revenue has contracted by 36% YoY
Nektar Therapeutics's gross margin has increased by 34% YoY

Price vs fundamentals

How does NKTR's price correlate with its fundamentals

Growth

What is Nektar Therapeutics's growth rate over time

Valuation

What is Nektar Therapeutics stock price valuation
P/E
N/A
P/B
3.51
P/S
31.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
41.68
Nektar Therapeutics's EPS has increased by 15% QoQ and by 13% YoY
The stock's P/S is 88% more than its last 4 quarters average of 16.7
The revenue has contracted by 36% YoY

Efficiency

How efficient is Nektar Therapeutics business performance
Nektar Therapeutics's return on sales has shrunk by 92% YoY but it has increased by 7% QoQ
Nektar Therapeutics's ROE has soared by 78% from the previous quarter and by 67% YoY
NKTR's ROA is up by 35% from the previous quarter and by 7% YoY
The return on invested capital has grown by 32% since the previous quarter but it has declined by 7% year-on-year

Dividends

What is NKTR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NKTR.

Financial health

How did Nektar Therapeutics financials performed over time
Nektar Therapeutics's total assets has soared by 198% YoY and by 172% from the previous quarter
Nektar Therapeutics's quick ratio has soared by 115% from the previous quarter
The debt is 86% lower than the equity
The debt to equity has shrunk by 98% YoY and by 85% QoQ
The debt has decreased by 17% YoY and by 3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.